Skip to main content

Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

The Original Article was published on 10 October 2019

Correction to: Mol Cancer (2019) 18:141

https://doi.org/10.1186/s12943-019-1064-5

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 3; specifically the left hand side of Fig. 3d.

Fig. 3
figure1

PVT1 suppression by PVT1 ASOs inhibits EAC cells growth in vitro and in vivo. a PVT1 expression in EAC cell lines (FLO1, SK-GT-4, JHESO, and OE19) and normal esophageal epithelial cell line HET-1A were determined by realtime qPCR analysis. b PVT1 expression was analyzed by qPCR in PVT1 ASOs treated EAC cell lines. PVT1 specific antisense oligonucleotides (ASO4 and ASO5) reduced PVT1 expression in dose-dependent manner in three EAC cell lines. c and d. Inhibition of PVT1 by ASOs significantly suppressed colony formation (c) and decreased cell invasion (d) in both JHESO and OE19 cells in two individual PVT1 ASOs respectively. e Average tumor volume in mice that treated with PVT1 ASO4 or control ASO via subcutaneous injection for 3 weeks (left). Actual tumor weights were retrieved from the mice at the termination of the experiment (middle). Representative tumors after scarified were shown (right). f The expression of PVT1 in mouse tumor tissues measured by qPCR has been shown significant reduction upon treatment with PVT1 ASO4 compared to the control group. Error bars, mean ± SEM. *, P < 0.05; **, P < 0.01

The corrected figure is given below. The correction does not have any effect on the results or conclusions of the paper.

Reference

  1. 1.

    Xu Y, Li Y, Jin J, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019;18:141 https://doi.org/10.1186/s12943-019-1064-5.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Zhenning Wang or Shumei Song or Jaffer A. Ajani.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, Y., Li, Y., Jin, J. et al. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 20, 56 (2021). https://doi.org/10.1186/s12943-021-01351-5

Download citation

\